The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...